Project Grant R01HL178849
Award Date
6/15/25
Completion Date
3/31/29
Dollars Obligated
$811K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $300,000.00 to The Trustees of the University of Pennsylvania to support the development of "A NOVEL CAR T-CELL THERAPY FOR SELECTIVE DEPLETION OF AUTOIMMUNE B CELLS IN LUPUS". The award period runs from August 1, 2025 to July 31, 2027. This research aims to advance innovative approaches to treating autoimmune disorders,...
This $170,555 Project Grant was awarded by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research to investigate the feasibility and effects of using Chimeric Antigen Receptor (CAR) T cell therapies targeting Fibroblast Activation Protein (FAP) as a potential treatment for cardiac fibrosis. The key objectives are to compare FAP CAR T cells to other T...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research (CFDA 93.396) program provides $587,108 to The Trustees of the University of Pennsylvania to conduct research aimed at enhancing the efficacy and durability of chimeric antigen receptor (CAR) T cell immunotherapy for cancer treatment. The key objectives are to improve the transduction efficiency and functional characteristics of non-activated CAR T cells by modulating the type I interferon (IFN1) signaling...
This $144,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the immunologic mechanisms underlying the development of Chagas cardiomyopathy, a debilitating heart condition that affects 30-40% of individuals infected with Trypanosoma cruzi. The research will use advanced techniques like single-cell RNA sequencing and spatial transcriptomics to characterize the immune cell...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH's Cardiovascular Diseases Research Program (CFDA 93.837), provides $5,154,906 to Versiti Wisconsin, Inc. to conduct a coordinated, multi-disciplinary investigation of molecular mechanisms underlying clinically important immune-mediated thrombocytopenic and thrombotic disorders. The award supports three interdependent research projects: (1) examining the immunobiology of fetal/neonatal...
This Project Grant award for $395,314, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to define the innate immune cell profile associated with the development of inhibitory antibodies against Factor VIII (FVIII) in individuals with hemophilia A. The central goals are to: 1) Characterize the cytokine microenvironment and role of conventional dendritic cells (cDC2) in activating CD4+ T cells and inducing...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $561,030 to the Children's Research Institute to study the impact of CD52 knockout on the function of multi-virus-specific T cells. The goal is to determine if CD52 knockout can enable T cell persistence and efficacy in the presence of the immunosuppressive drug alemtuzumab. Key activities include optimizing CRISPR/Cas9 editing of virus-specific T cells,...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director (CFDA 93.310 - Trans-NIH Research Support) provides $406,249 to the Trustees of the University of Pennsylvania to investigate how chimeric antigen receptor (CAR) T cell therapy can be improved for treating solid tumors. The primary goals are to: Define the tumor and stromal features that influence CAR T cell infiltration and function. Determine the impact of CAR T cell functional profile on...
This $300,000 federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to engineer human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting NTPDase3 on B cells for controlling type 1 diabetes (T1D). The project, led by Sanford Research, will test CAR Tregs with varying antigen binding affinities to optimize their activation, proliferation, and suppressive function against islet-reactive T...